AMGN Stock Analysis — Amgen
Sector: Healthcare
AI Verdict
Amgen trades at a big discount to the healthcare sector on forward earnings despite blockbuster growth forecasts, so the numbers look cheap if its biologic drug pipeline delivers.
Competitive Moat
Amgen specializes in biologic drugs for chronic diseases, leveraging a deep pipeline and manufacturing expertise in complex molecules that are difficult to replicate. Its scale and intellectual property position create high barriers to entry for competitors in biosimilars and innovative therapies.
Summary
Amgen's forward P/E of 15.2x with 65.3% expected EPS growth puts it in rare territory for a big-cap pharma stock.
Where It Stands
Shares are up 30.36% over the past year, RSI sits at 61.3 (neutral but edging toward elevated), and the stock trades at 15.2x forward earnings versus a healthcare median of 22x.
Key Metrics
- RSI: 61.3 — Near Overbought
- Trailing P/E: 25.1x
- Forward P/E: 15.2x
- PEG Ratio: 0.39
- Earnings Growth: +0.7%
- Revenue Growth: +0.1%
- Market Cap: $195.2B
- Dividend Yield: 0.03%
- 1-Year Return: 30.36%
- 52-Week High: $391.29
- 52-Week Low: $269.77
Analyst Consensus
22 Buy · 19 Hold · 3 Sell (44 analysts)
Bull Case
You're paying just 15.2x next year's earnings for 65.3% expected EPS growth, which is cheap for the growth on offer in this sector.
Bear Case
If the forward P/E reverts to the sector median of 22x without delivering the forecasted growth, the stock could see a sharp correction from current expectations.
Catalyst to Watch
Watch for FDA approvals or major clinical trial readouts, as these will determine if the 65.3% EPS growth forecast is credible.